FDA Approves New Indication for Avapritinib

Avapritinib (AYVAKIT) is now approved to treat adults with indolent systemic mastocytosis.
Medscape Medical News

source https://www.medscape.com/viewarticle/992323?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

Heart Failure Care Outside of ICU Can Lower Cost